Orion Oyj (OTCMKTS:ORINY) Reaches New 1-Year High at $28.55

Orion Oyj (OTCMKTS:ORINYGet Free Report)’s stock price reached a new 52-week high on Friday . The company traded as high as $28.55 and last traded at $28.55, with a volume of 203 shares trading hands. The stock had previously closed at $27.15.

Orion Oyj Price Performance

The company has a current ratio of 2.39, a quick ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market cap of $8.06 billion, a price-to-earnings ratio of 33.99 and a beta of 0.21. The stock has a 50-day moving average of $24.87 and a two-hundred day moving average of $21.45.

Orion Oyj (OTCMKTS:ORINYGet Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.17 earnings per share for the quarter. Orion Oyj had a return on equity of 27.97% and a net margin of 18.08%. The business had revenue of $332.07 million during the quarter. On average, analysts anticipate that Orion Oyj will post 1.11 EPS for the current year.

Orion Oyj Company Profile

(Get Free Report)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.

Read More

Receive News & Ratings for Orion Oyj Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion Oyj and related companies with MarketBeat.com's FREE daily email newsletter.